About 60 million rubles have been raised for the treatment of a boy from Dagestan.

In the first days of Ramadan, more than a quarter of the amount needed for the treatment of a 9-year-old boy from Dagestan with Duchenne muscular dystrophy was raised. A total of 230 million rubles are needed.

As reported by the "Caucasian Knot," 230 million rubles were needed for the treatment of a 10-year-old boy from the Suleiman-Stalsky district with Duchenne muscular dystrophy. 70 million were raised in six months, and another 160 million were raised in five days.

Already 60 million rubles for the treatment of a 9-year-old boy have been raised in the first days of Ramadan, Novoye Delo reported today.

An emergency fundraising campaign is underway to treat a 9-year-old boy from Makhachkala with the rare, fatal disease "Duchenne muscular dystrophy." A disease that gradually weakens and wastes muscles threatens health and life. A total of 230 million rubles is being raised for treatment with the expensive drug Elevidys, the publication states.

"This disease saps strength every day. The condition of these children worsens every day. First of all, their legs give out and they stop walking," his mother wrote on an Instagram* page created to raise funds for the boy.

We Muslims must not be left behind.

This post has garnered 3,120 comments. Their authors wish the boy a speedy recovery.

"May Allah grant him healing. I believe that we will unite and raise everything like last time, with the help of the Almighty," writes, in particular, dr.ahmedjanova.

"In sha Allah, we will raise this amount; we Muslims must not be left behind," writes sabinaderbentt.

The social media account states that money is also being collected offline, in stores and parks. In particular, collection jars have been set up in stores in Stavropol.

The "Pure Heart" foundation is collecting funds, and posts calling for help for the child have been posted on its Telegram channel. The foundation offers donations through the app or by transferring funds to the boy's mother's card.

Duchenne disease (Duchenne muscular dystrophy) is diagnosed in approximately one in 3,500 to 4,000 boys and is characterized by progressive muscular dystrophy that manifests itself in early childhood and leads to the inability to walk in the second decade of life and, in most cases, to death in the second or third decade of life, pediatrician Evgeny Zolotov previously told a Caucasian Knot correspondent.

"The disease is caused by a change (mutation, most often a deletion or duplication) in the dystrophin gene, located on the X chromosome. The gene that causes the disease is located on the X chromosome, and therefore the disease is much more severe "It's expressed in boys because they only have one X chromosome," he noted. He added that this is a very rare and highly specialized area of ​​expertise among doctors.

The Circle of Goodness Foundation, which is procuring the drug, states the criteria on its website as follows: "According to the results of clinical trials and the manufacturer's instructions, the drug is indicated for children aged 4–5 years." At the same time, the foundation notes that "high-profile charitable fundraising for private donations has begun in Russia for Elevidis therapy for children significantly older than 4-5 years old, namely for age groups over 7 years old, for whom the drug has not shown significant efficacy, or studies have not been conducted at all."

We expect that the progression of the disease will slow down.

Tatyana Gremyakova, Doctor of Medical Sciences, President and Medical Director of the Gordey Foundation for the Development of Systematic Care for Patients with Duchenne Muscular Dystrophy, and Head of the Children's High-Tech Neuromuscular Center at the Central Clinical Hospital with a Polyclinic of the Presidential Executive Office of the Russian Federation, notes that in the United States there have been cases of the drug being used in patients over 20 years old.

"With this drug, we don't expect the child to get up, run, and become completely healthy – we expect That the disease's progression will slow. That the disease's trajectory will change, that it won't be steep but rather much flatter. That children will have a long period of early growth and development, and that they will have time to mature by the time the disease plateaus and even worsens. "That they will have quite a long time before they can walk," Miloserdie.ru quotes her as saying.